Suchergebnisse - "Antonioli, Elisabetta"

PubPharm (102)

1

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

2

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma : a prospective real-life experience of the Regional Tuscan Myeloma Network

enthalten in: Frontiers in oncology | 2023

von Antonioli, E. | Pilerci, S. | Attucci, I. | +13

3

A multidisciplinary case report of multiple myeloma with renal and cardiac involvement : a look beyond amyloidosis

enthalten in: BMC nephrology | 2022

von Innocenti, S. | Bacchi, B. | Allinovi, M. | +7

4

A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis

enthalten in: BMC nephrology | 2022

von Innocenti, S. | Bacchi, B. | Allinovi, M. | +7

5

A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis

enthalten in: BMC nephrology | 2022

von Innocenti, S. | Bacchi, B. | Allinovi, M. | +7

6

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

7

Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma : A retro-prospective observational study

enthalten in: European journal of haematology | 2022

von Del Giudice, M. | Gozzetti, A. | Antonioli, E. | +9

8

Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK : a GIMEMA, multicentre, cross-sectional study

enthalten in: The lancet. Healthy longevity | 2022

von Efficace, F. | Gaidano, G. | Petrucci, M. | +18

CommentIn: Lancet Healthy Longev. 2022 Sep;3(9):e579-e580. - PMID 36102770

9

Daratumumab in AL Amyloidosis : A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network)

enthalten in: Journal of personalized medicine | 2022

von Sammartano, V. | Antonioli, E. | Buda, G. | +11

10

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological Oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]